The elimination of HCV (hepatitis C virus) infection is, according to WHO (World Health Organization), of international interest. With new diagnostic tools and treatment possibilities, one major challenge for the elimination is to involve infected patients, especially those from socially excluded subpopulations, into HCV infection-treatment programs. The key question is how to help people who inject drugs (PWID) to engage in HCV infection-treatment programs and improve communication between PWID and hepatologists or other medical professionals involved in the treatment of chronic HCV infection. Furthermore, the medical professionals have to accept the changing spectrum of patients with chronic viral hepatitis. Without close interdisciplinary cooperation, it would be extremely difficult to achieve the WHO goal of global viral hepatitis C elimination. Here, we try to encourage our colleagues as well as addictologists and social workers to play their crucial part in the viral hepatitis C eradication process. It is extremely important for the healthcare providers to be able to communicate with addicted clients, inform PWID about the latest developments in the diagnosis and HCV infection treatment, and get them motivated to engage with specialized treatment programs.

4th Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Kateřinská 32 128 00 Prague 2 Czech Republic

Department of Addictology 1st Faculty of Medicine Charles University Prague Kateřinská 32 128 00 Prague 2 Czech Republic

Division of Infectious Diseases and Vaccinology School of Public Health University of California Berkeley CA 94720 USA

Remedis s r o Vladimírova 10 140 00 Prague 4 Czech Republic

See more in PubMed

World Health Organization . Global Hepatitis Report, 2017. World Health Organization; Geneva, Switzerland: 2017.

World Health Organization . Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection. World Health Organization; Geneva, Switzerland: 2016.

Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., Hatzakis A., Prins M., Vickerman P., Lazarus J., et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS ONE. 2014;9:e103345. doi: 10.1371/journal.pone.0103345. PubMed DOI PMC

World Health Organization . Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards Ending Viral Hepatitis. World Health Organization; Geneva, Switzerland: 2016.

World Health Organization . Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. World Health Organization; Geneva, Switzerland: 2016.

Yousafzai M.T., Bajis S., Alavi M., Grebely J., Dore G.J., Hajarizadeh B. Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. J. Viral Hepat. 2021;28:1340–1354. doi: 10.1111/jvh.13574. PubMed DOI

The Polaris Observatory HCV Collaborators Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol. 2017;2:161–176. doi: 10.1016/S2468-1253(16)30181-9. PubMed DOI

Razavi H., ElKhoury A.C., Elbasha E., Estes C., Pasini K., Poynard T., Kumar R. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57:2164–2170. doi: 10.1002/hep.26218. PubMed DOI PMC

Zibell J.E., Igball K., Patel R.C. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb. Mortal Wkly Rep. 2015;64:453–458. PubMed PMC

Suryaprasad A.G., White J.Z., Xu F., Eichler B.-A., Hamilton J., Patel A., Hamdounia S.B., Church D.R., Barton K., Fisher C., et al. Emerging Epidemic of Hepatitis C Virus Infections among Young Nonurban Persons Who Inject Drugs in the United States, 2006–2012. Clin. Infect. Dis. 2014;59:1411–1419. doi: 10.1093/cid/ciu643. PubMed DOI

Hajarizadeh B., Cunningham E.B., Reid H., Law M., Dore G.J., Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2018;3:754–767. doi: 10.1016/S2468-1253(18)30304-2. PubMed DOI

Grebely J., Larney S., Peacock A., Colledge S., Leung J., Hickman M., Vickerman P., Blach S., Cunningham E.B., Dumchev K., et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114:150–166. doi: 10.1111/add.14393. PubMed DOI PMC

Degenhardt L., Peacock A., Colledge S., Leung J., Grebely J., Vickerman P., Stone J., Cunningham E.B., Trickey A., Dumchev K., et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob. Health. 2017;5:e1192–e1207. doi: 10.1016/S2214-109X(17)30375-3. PubMed DOI PMC

Degenhardt L., Charlson F., Stanaway J., Larney S., Alexander L.T., Hickman M., Cowie B., Hall W.D., Strang J., Whiteford H., et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: Findings from the Global Burden of Disease Study 2013. Lancet Infect. Dis. 2016;16:1385–1398. doi: 10.1016/S1473-3099(16)30325-5. PubMed DOI

Razavi H., Robbins S., Zeuzem S., Negro F., Buti M., Duberg A.-S., Roudot-Thoraval F., Craxi A., Manns M., Marinho R.T., et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol. Hepatol. 2017;2:325–336. doi: 10.1016/S2468-1253(17)30045-6. PubMed DOI

U.S. Food and Drug Administration In Proceedings of the Antiviral Drugs Advisory Committee Meeting; Silver Spring, MD, USA. 27–28 April 2011.

Stanaway J.D., Flaxman A.D., Naghavi M., Fitzmaurice C., Vos T., Abubakar I., Abu-Raddad L.J., Assadi R., Bhala N., Cowie B., et al. The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081–1088. doi: 10.1016/S0140-6736(16)30579-7. PubMed DOI PMC

Hickman M., De Angelis D., Vickerman P., Hutchinson S., Martin N.K. Hepatitis C virus treatment as prevention in people who inject drugs: Testing the evidence. Curr. Opin. Infect. Dis. 2015;28:576–582. doi: 10.1097/QCO.0000000000000216. PubMed DOI PMC

Zoulim F., Liang T.J., Gerbes A.L., Aghemo A., Deuffic-Burban S., Dusheiko G.M., Fried M.W., Pol S., Rockstroh J.K., A Terrault N., et al. Hepatitis C virus treatment in the real world: Optimising treatment and access to therapies. Gut. 2015;64:1824–1833. doi: 10.1136/gutjnl-2015-310421. PubMed DOI PMC

Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 2016;64:486–504. doi: 10.1016/j.jhep.2015.09.011. PubMed DOI

Ceccherini-Silberstein F., Cento V., Di Maio V.C., Perno C.F., Craxì A. Viral resistance in HCV infection. Curr. Opin. Virol. 2018;32:115–127. doi: 10.1016/j.coviro.2018.10.005. PubMed DOI

Hezode C., Reau N., Svarovskaia E.S., Doehle B.P., Shanmugam R., Dvory-Sobol H., Hedskog C., McNally J., Osinusi A., Brainard D.M., et al. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J. Hepatol. 2018;68:895–903. doi: 10.1016/j.jhep.2017.11.032. PubMed DOI

Chhatwal J., Chen Q., Ayer T., Bethea E.D., Kanwal F., Kowdley K.V., Wang X., Roberts M.S., Gordon S.C. Hepatitis C virus re-treatment in the era of direct-acting antivirals: Projections in the USA. Aliment. Pharmacol. Ther. 2018;47:1023–1031. doi: 10.1111/apt.14527. PubMed DOI PMC

Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J. Hepatol. 2021;74:1472–1482. doi: 10.1016/j.jhep.2021.03.004. PubMed DOI

Abravanel F., Métivier S., Chauveau M., Péron J.-M., Izopet J. Transmission of HCV NS5A Inhibitor–Resistant Variants Among HIV-Infected Men Who Have Sex with Men. Clin. Infect. Dis. 2016;63:1271–1272. doi: 10.1093/cid/ciw554. PubMed DOI

Centers for Disease Control and Prevention (CDC) Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR Morb. Mortal Wkly Rep. 2013;62:362–365. PubMed PMC

Major M.E., Rehermann B., Feinstone S.M. Hepatitis C viruses. In: Fields B.N., Knipe D.M., Howley P.M., Griffin D.E., editors. Fields Virology. 4th ed. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2001. pp. 1127–1161.

Lau J.Y., Davis G.L., Prescott L.E., Maertens G., Lindsay K.L., Qian K., Mizokami M., Simmonds P. Distribution of Hepatitis C Virus Genotypes Determined by Line Probe Assay in Patients with Chronic Hepatitis C Seen at Tertiary Referral Centers in the United States. Ann. Intern. Med. 1996;124:868–876. doi: 10.7326/0003-4819-124-10-199605150-00002. PubMed DOI

Li J.-S., Tong S.-P., Vitvitski L., Trépo C. Single-step nested polymerase chain reaction for detection of different genotypes of hepatitis C virus. J. Med. Virol. 1995;45:151–155. doi: 10.1002/jmv.1890450207. PubMed DOI

Stuyver L., Rossau R., Wyseur A., Duhamel M., VanderBorght B., Van Heuverswyn H., Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J. Gen. Virol. 1993;74:1093–1102. doi: 10.1099/0022-1317-74-6-1093. PubMed DOI

HCV Guidance HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. AASLD. [(accessed on 16 March 2021)]. Available online: https://www.hcvguidelines.org/unique-populations/acute-infection.

Lim J.K., Flamm S.L., Singh S., Falck-Ytter Y.T., Gerson L., Hirano I., Nguyen G.C., Rubenstein J.H., Smalley W.E., Stollman N., et al. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology. 2017;152:1536–1543. doi: 10.1053/j.gastro.2017.03.017. PubMed DOI

Flisiak R., Jaroszewicz J., Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin. Emerg. Drugs. 2013;18:461–475. doi: 10.1517/14728214.2013.847089. PubMed DOI

Martinot-Peignoux M., Stern C., Maylin S., Ripault M.-P., Boyer N., LeClere L., Castelnau C., Giuily N., El Ray A., Cardoso A.-C., et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122–1126. doi: 10.1002/hep.23444. PubMed DOI

Maylin S., Martinot–Peignoux M., Moucari R., Boyer N., Ripault M., Cazals–Hatem D., Giuily N., Castelnau C., Cardoso A.C., Asselah T., et al. Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C. Gastroenterology. 2008;135:821–829. doi: 10.1053/j.gastro.2008.05.044. PubMed DOI

Simmons B., Saleem J., Hill A., Riley R.D., Cooke G.S. Risk of Late Relapse or Reinfection with Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin. Infect. Dis. 2016;62:683–694. doi: 10.1093/cid/civ948. PubMed DOI PMC

Afdhal N., Everson G.T., Calleja J.L., Mccaughan G., Bosch J., Brainard D.M., McHutchison J.G., De-Oertel S., An D., Charlton M., et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J. Viral Hepat. 2017;24:823–831. doi: 10.1111/jvh.12706. PubMed DOI

Kim R.W., Mannalithara A., Lee H., Osinusi A., Schall R.E.A., Brainard D.M. Survival benefit of direct acting antiviral therapy in patients with decompensated cirrhosis. Hepatology. 2017;66:LB27. doi: 10.1016/S0168-8278(18)30387-8. DOI

European Association for the Study of the Liver EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018;69:461–511. doi: 10.1016/j.jhep.2018.03.026. PubMed DOI

Pawlotsky J.M., Negro F., Aghemo A., Berenguer M., Dalgard O., Dusheiko G., Marra F., Puoti M., Wedemeyer H., European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018. PubMed DOI